Evaluation of WHO criteria for diagnosis of polycythemia vera: A prospective analysis

Blood

Volumn 122, Issue 11, 2013, Pages 1881-1886

  Silver, Richard T ^a   Chow, William ^a   Orazi, Attilio ^a   Arles, Stephen P ^a   Goldsmith, Stanley J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; JANUS KINASE 2;

ADULT; AGED; ARTICLE; BONE MARROW EXAMINATION; CLINICAL ARTICLE; DISEASE CLASSIFICATION; ERYTHROCYTE; ERYTHROCYTE VOLUME; FEMALE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOCYTHEMIA; WORLD HEALTH ORGANIZATION; BLOOD; BONE MARROW; ENZYMOLOGY; EVALUATION; METABOLISM; PATHOLOGY; PRACTICE GUIDELINE; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STANDARD;

BONE MARROW; ERYTHROCYTE VOLUME; ERYTHROPOIETIN; HEMATOCRIT; HEMOGLOBINS; HUMANS; JANUS KINASE 2; POLYCYTHEMIA VERA; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; WORLD HEALTH ORGANIZATION;

EID: 84887373344     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-06-508416     Document Type: Article

References (40)

1. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092-1097.
2. Silver RT, Chow W, Vandris K, et al. Prospective evaluation of the World Health Organization criteria for the diagnosis of polycythemia vera [abstract] Blood. 2011;118(21). Abstract 3837.
3. Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood. 2008;112(2):231-239.
4. Barbui T, Barosi G, Birgegard G, et al; European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761-770.
5. Marchioli R, Finazzi G, Specchia G, et al CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22-33.
6. Wang YL, Vandris K, Jones A, Cross NC, Christos P, Adriano F, Silver RT. JAK2 Mutations are present in all cases of polycythemia vera. Leukemia. 2008;22(6):1289.
7. Pearson TC, Guthrie DL, Simpson J, et al. Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br J Haematol. 1995;89(4):748-756.
8. Lorberboym M, Rahimi-Levene N, Lipszyc H, Kim CK. Analysis of red cell mass and plasma volume in patients with polycythemia. Arch Pathol Lab Med. 2005;129(1):89-91.
9. Johansson PL, Safai-Kutti S, Kutti J. An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia. Br J Haematol. 2005;129(5):701-705.
10. Alvarez-Larrán A, Ancochea A, Angona A, et al. Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia. Haematologica. 2012;97(11):1704-1707.
11. Cassinat B, Laguillier C, Gardin C, et al; PV-Nord Group. Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass? Leukemia. 2008;22(2):452-453.
12. Najean Y, Dresch C, Rain J, Chomienne C. Radioisotope investigations for the diagnosis and follow-up of polycythemic patients. In: Wasserman LR, Berk PD, Berlin NI, eds. Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia, PA: Saunders; 1995:79-90.
13. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100(13):4272-4290.
14. Fairbanks VF, Klee GG, Wiseman GA, Hoyer JD, Tefferi A, Petitt RM, Silverstein MN. Measurement of blood volume and red cell mass: re-examination of 51Cr and 125I methods. Blood Cells Mol Dis. 1996;22(2):169-186, discussion 186a-186g.
15. Moralidis E, Papanastassiou E, Arsos G, Chilidis I, Gerasimou G, Gotzamani-Psarrakou A. A single measurement with (51)Cr-tagged red cells or (125)I-labeled human serum albumin in the prediction of fractional and whole blood volumes: an assessment of the limitations. Physiol Meas. 2009;30(7):559-571.
16. Balga I, Solenthaler M, Furlan M. Should whole-body red cell mass be measured or calculated? Blood Cells Mol Dis. 2000;26(1):25-31, discussion 32-36.
17. Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012;87(3):285-293.
18. Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood. 2008;111(1):60-70.
19. Thiele J, Kvasnicka HM, Müllauer L, Buxhofer-Ausch V, Gisslinger B, Gisslinger H. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood. 2011;117(21):5710-5718.
20. Thiele J, Kvasnicka HM, Orazi A. Bone marrow histopathology in myeloproliferative disorders - current diagnostic approach. Semin Hematol. 2005;42(4):184-195.
21. Ellis JT, Silver RT, Coleman M, Geller SA. The bone marrow in polycythemia vera. Semin Hematol. 1975;12(4):433-444.
22. World Health Organization. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
23. Chen Q, Lu P, Jones AV, Cross NC, Silver RT, Wang YL. Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders. J Mol Diagn. 2007;9(2):272-276.
24. Recommended methods for measurement of red-cell and plasma volume: International Committee for Standardization in Haematology. J Nucl Med. 1980;21(8):793-800.
25. Leslie WD, Dupont JO, Peterdy AE. Effect of obesity on red cell mass results. J Nucl Med. 1999;40(3):422-428.
26. Manoharan A, Horsley R, Pitney WR. The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol. 1979;43(2):185-190.
27. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128-1132.
28. Mossuz P, Girodon F, Donnard M, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica. 2004;89(10):1194-1198.
29. Sirhan S, Fairbanks VF, Tefferi A. Red cell mass and plasma volume measurements in polycythemia: evaluation of performance and practical utility. Cancer. 2005;104(1):213-215.
30. Thiele J, Kvasnicka HM, Diehl V. Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. Acta Haematol. 2005;113(4):213-219.
31. Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol. 2013;6(1):49-58.
32. Silver RT, Vandris K, Goldman JJ. Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report. Blood. 2011;117(24):6669-6672.
33. Hasselbalch HC. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol. 2011;4(6):637-655.
34. Pearson TC. Apparent polycythaemia. Blood Rev. 1991;5(4):205-213.
35. Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol. 2010;85(1):62-69.
36. Gianelli U, Iurlo A, Vener C, et al. The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the "early" prepolycythemic phase of polycythemia vera and essential thrombocythemia. Am J Clin Pathol. 2008;130(3):336-342.
37. Najfeld V. Conventional and molecular cytogenetics of Ph-negative chronic myeloproliferative disorders. In: Silver RT, Tefferi A, eds. Myeloproliferative Disorders. New York, NY: Informa Healthcare; 2008:51-68.
38. Wang X, LeBlanc A, Gruenstein S, et al. Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms. Exp Hematol. 2009;37(10):1194-1200.
39. Tefferi A. Diagnosing polycythemia vera: a paradigm shift. Mayo Clin Proc. 1999;74(2):159-162.
40. Verstovsek S, Silver RT, Cross NC, Tefferi A. JAK2V617F mutational frequency in polycythemia vera: 100%, <90%, less? Leukemia. 2006;20(11):2067.